Member Info for Hurst10

Richemont results

Boehringer's latest deal with Oxford Bio therapeutics:

that the company’s investment in ADCs will go toward “addressing the novel tumor target space to develop next-generation cancer treatments.”

More to come and CC is getting ready.

Next time you are let out from the basement, would you mind remind us all of your target price ?

With the news flow accelerating, timing as always is everything.

Our US CEO is aware of this and to have long awaited news out later today or this week, with Avacta becoming a Therapeutic company, re- rating and Nasdaq listing, the company no doubt will be in conversation with leading investment banks, in front of the major Healthcare/ Biotech conference held by JPM next week in the US.

"The 43rd Annual Healthcare Conference will take place on January 13-16, 2025 in San Francisco, CA.

This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community."

Your opinion?

Buy or sell?

Target price

If you do not have a view,

Pls do not waste our time any more

Stay in the cellar

It is always good to see your comments , as you are always wrong .

Please remind us what is you " current " view, bull or bear ?

+ target price. You have 2 hours left to come up with something entertaining, always impressed you can get a signal from the cellar.

More 200/ buy prints

Novartis is also upgrading their forecast.

Novartis is betting that new treatments for cancer and immunological diseases will drive growth in the medium term above previously expected levels. The company said Thursday that sales are forecast to increase 6% a year through 2028, up from an earlier estimate of 5%, also boosted by drugs for neurological and cardiovascular conditions.

Novartis continues their M&A.

Making good on comments from its meet the management event around "value-creating bolt-ons," Novartis announced Thursday the acquisition of Kate Therapeutics (KateTx) for up to $1.1 billion, bolstering its pipeline in the key areas of gene therapy and neuroscience.

Robert Baloh, global head of neuroscience research at the Swiss drugmaker, noted that the deal "reflects our commitment to addressing unmet medical needs in neuroscience and tackling the limitations of existing gene therapies for patients with inherited neuromuscular

Do we have the note from Peel H ?

CC up early and will have enquires from State side : "when? "

Watch out for the pre size buys at 51/2 , bid is going to jump now, so size better get a move on and they will happily pay 55, could be a very lively afternoon and indeed Friday with a DX RNS .

The way CC likes to do it

PH note and the timing is To remind the company (AVCT) that they exist before the major US broker is announced to be lead on a upcoming IPO, (ex DX ) with a very different target price.

Goldman's or Jefferies to lead and the rest of the usual biotech brokers will

Follow and do as the lead book runner tells them to do.

Oncology heavyweight Merck & Co. became the latest to throw its hat into the PD-1/VEGF bispecific antibody ring through a licensing deal with Chinese biotech LaNova Medicines. The agreement to develop LM-299 includes an upfront payment of $588 million, with LaNova eligible for further milestones of up to $2.7 billion.

It certainly highlights the Affimer platform and it's value creating Bispecific Antibodies.

Size buyers moving in early .

Who can blame them

Trump victory likely to boost deal-making in 2025, changes at FTC will benefit deals already in the works.

M&A, BIO IPO and Healthcare sector ready to take off with a “ deal friendly “ president keeping an eye on the FTC. This will Only increase the prospective valuation of the sector and an Avacta Therapeutics IPO.

Ex DCX and an official confirmation of US IPO and with the first licence deal in the pocket!

We be there sooner rather than later.

Just remind us of your target price!!!

Another deal in the sector, licence deal coming our way .

“

AbbVie and EvolveImmune Therapeutics sign oncology collaboration

EvolveImmune is now eligible for an aggregate of $65m in upfront fees and equity investment from AbbVie.”

Try size and current offer price!

Great that the majority of us keep buying on silly MM days, the market needs to be careful, the company is in an incredible position, Licence deal, DCX sale and or IPO?

Quite a month ahead of us !!

Another close with interesting post hours trades 1,9 mill shares etc

Bad luck to everybody, stock up 60% and placing done and now we have this item/ person onboard, famous for always having an opinion about anything apart from stock and shares. Impressive that he gets a signal from the cellar!!

It was suggested : $1bill per functional AVA